FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:1092-1102 March 17, 2005 Number 11 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Drazen, J. M. Editorial by Psaty, B. M. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

ABSTRACT

Background Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but only limited long-term data have been available for analysis. We report on the cardiovascular outcomes associated with the use of the selective COX-2 inhibitor rofecoxib in a long-term, multicenter, randomized, placebo-controlled, double-blind trial designed to determine the effect of three years of treatment with rofecoxib on the risk of recurrent neoplastic polyps of the large bowel in patients with a history of colorectal adenomas.

Methods A total of 2586 patients with a history of colorectal adenomas underwent randomization: 1287 were assigned to receive 25 mg of rofecoxib daily, and 1299 to receive placebo. All investigator-reported serious adverse events that represented potential thrombotic cardiovascular events were adjudicated in a blinded fashion by an external committee.

Results A total of 46 patients in the rofecoxib group had a confirmed thrombotic event during 3059 patient-years of follow-up (1.50 events per 100 patient-years), as compared with 26 patients in the placebo group during 3327 patient-years of follow-up (0.78 event per 100 patient-years); the corresponding relative risk was 1.92 (95 percent confidence interval, 1.19 to 3.11; P=0.008). The increased relative risk became apparent after 18 months of treatment; during the first 18 months, the event rates were similar in the two groups. The results primarily reflect a greater number of myocardial infarctions and ischemic cerebrovascular events in the rofecoxib group. There was earlier separation (at approximately five months) between groups in the incidence of nonadjudicated investigator-reported congestive heart failure, pulmonary edema, or cardiac failure (hazard ratio for the comparison of the rofecoxib group with the placebo group, 4.61; 95 percent confidence interval, 1.50 to 18.83). Overall and cardiovascular mortality was similar in the two groups.

Conclusions Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk.

Source Information

From the Department of Gastrointestinal Medicine and Nutrition, University of Texas M.D. Anderson Cancer Center, Houston (R.S.B.); the Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill (R.S.S.); Merck Research Laboratories, West Point, Pa. (H.Q., J.A. Bolognese, B.O., K.H., C.L.); the Department of Pathology, Mount Sinai Hospital, Toronto (R.R.); the Department of Surgery, University of Birmingham, Birmingham, United Kingdom (D.M.); the Department of Medicine, Clinic University Hospital, Zaragoza, Spain (A.L.); the Department of Medicine, Tufts–New England Medical Center, Boston (M.A.K.); and the Departments of Medicine and Community and Family Medicine, Dartmouth Medical School, Hanover, N.H. (J.A. Baron).

This article was published at www.nejm.org on February 15, 2005.

Address reprint requests to Dr. Bresalier at the Department of Gastrointestinal Medicine and Nutrition, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030-4009, or at rbresali{at}mdanderson.org.

Full Text of this Article

Related Letters:

Adverse Cardiovascular Effects of Rofecoxib
Nissen S. E., Furberg C. D., Bresalier R. S., Baron J. A.
Extract | Full Text | PDF  
N Engl J Med 2006; 355:203-205, Jul 13, 2006; published at www.nejm.org on Jun 26, 2006 (10.1056/NEJMc066260). Correspondence

This article has been cited by other articles:

• Panoulas, V. F., Metsios, G. S., Pace, A. V., John, H., Treharne, G. J., Banks, M. J., Kitas, G. D. (2008). Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 0: ken159v1-ken159 [Abstract] [Full Text]  
• Kirkpatrick, J. S., Stevens, T. (2008). The FDA Process for the Evaluation and Approval of Orthopaedic Devices. J Am Acad Orthop Surg 16: 260-267 [Abstract] [Full Text]  
• Nakanishi, M., Montrose, D. C., Clark, P., Nambiar, P. R., Belinsky, G. S., Claffey, K. P., Xu, D., Rosenberg, D. W. (2008). Genetic Deletion of mPGES-1 Suppresses Intestinal Tumorigenesis. Cancer Res. 68: 3251-3259 [Abstract] [Full Text]  
• Blaine, T., Moskowitz, R., Udell, J., Skyhar, M., Levin, R., Friedlander, J., Daley, M., Altman, R. (2008). Treatment of Persistent Shoulder Pain with Sodium Hyaluronate: A Randomized, Controlled Trial. A Multicenter Study. JBJS 90: 970-979 [Abstract] [Full Text]  
• Arehart, E., Stitham, J., Asselbergs, F. W., Douville, K., MacKenzie, T., Fetalvero, K. M., Gleim, S., Kasza, Z., Rao, Y., Martel, L., Segel, S., Robb, J., Kaplan, A., Simons, M., Powell, R. J., Moore, J. H., Rimm, E. B., Martin, K. A., Hwa, J. (2008). Acceleration of Cardiovascular Disease by a Dysfunctional Prostacyclin Receptor Mutation: Potential Implications for Cyclooxygenase-2 Inhibition. Circ. Res. 102: 986-993 [Abstract] [Full Text]  
• Solomon, S. D., Wittes, J., Finn, P. V., Fowler, R., Viner, J., Bertagnolli, M. M., Arber, N., Levin, B., Meinert, C. L., Martin, B., Pater, J. L., Goss, P. E., Lance, P., Obara, S., Chew, E. Y., Kim, J., Arndt, G., Hawk, E., for the Cross Trial Safety Assessment Group, (2008). Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis. Circulation 117: 2104-2113 [Abstract] [Full Text]  
• Psaty, B. M., Kronmal, R. A. (2008). Reporting Mortality Findings in Trials of Rofecoxib for Alzheimer Disease or Cognitive Impairment: A Case Study Based on Documents From Rofecoxib Litigation. JAMA 299: 1813-1817 [Abstract] [Full Text]  
• Ferrario, C. M. (2008). Editorial: On the selective inhibitors of Cyclooxygenase-2: Do we have a last word?. Therapeutic Advances in Cardiovascular Disease 2: 75-78  
• van Staa, T P, Smeeth, L, Persson, I, Parkinson, J, Leufkens, H G M (2008). What is the harm-benefit ratio of Cox-2 inhibitors?. Int J Epidemiol 37: 405-413 [Abstract] [Full Text]  
• Rouzer, C. A., Marnett, L. J. (2008). Non-redundant Functions of Cyclooxygenases: Oxygenation of Endocannabinoids. J. Biol. Chem. 283: 8065-8069 [Abstract] [Full Text]  
• Reid, J. M., Mandrekar, S. J., Carlson, E. C., Harmsen, W. S., Green, E. M., McGovern, R. M., Szabo, E., Ames, M. M., Boring, D., Limburg, P. J., for the Cancer Prevention Network, (2008). Comparative Bioavailability of Sulindac in Capsule and Tablet Formulations. Cancer Epidemiol. Biomarkers Prev. 17: 674-679 [Abstract] [Full Text]  
• Hennekens, C. H., Borzak, S. (2008). Cyclooxygenase-2 Inhibitors and Most Traditional Nonsteroidal Anti-inflammatory Drugs Cause Similar Moderately Increased Risks of Cardiovascular Disease. J CARDIOVASC PHARMACOL THER 13: 41-50 [Abstract]  
• Sidiropoulos, P. I., Hatemi, G., Song, I.-H., Avouac, J., Collantes, E., Hamuryudan, V., Herold, M., Kvien, T. K., Mielants, H., Mendoza, J. M., Olivieri, I., Ostergaard, M., Schachna, L., Sieper, J., Boumpas, D. T., Dougados, M. (2008). Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatology (Oxford) 47: 355-361 [Abstract] [Full Text]  
• Krueger, K, Lino, L, Dore, R, Radominski, S, Zhang, Y, Kaur, A, Simpson, R, Curtis, S (2008). Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). Ann Rheum Dis 67: 315-322 [Abstract] [Full Text]  
• Puccetti, L. (2008). Confounders were ignored. BMJ 336: 403-404 [Full Text]  
• Subbaramaiah, K., Hudis, C., Chang, S.-H., Hla, T., Dannenberg, A. J. (2008). EP2 and EP4 Receptors Regulate Aromatase Expression in Human Adipocytes and Breast Cancer Cells: EVIDENCE OF A BRCA1 AND p300 EXCHANGE. J. Biol. Chem. 283: 3433-3444 [Abstract] [Full Text]  
• Hong, T.-T., Huang, J., Barrett, T. D., Lucchesi, B. R. (2008). Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis. Am. J. Physiol. Heart Circ. Physiol. 294: H145-H155 [Abstract] [Full Text]  
• Zatelli, M. C., Luchin, A., Tagliati, F., Leoni, S., Piccin, D., Bondanelli, M., Rossi, R., degli Uberti, E. C (2007). Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. Endocr Relat Cancer 14: 1029-1038 [Abstract] [Full Text]  
• Joshi, G. P., Gertler, R., Fricker, R. (2007). Cardiovascular Thromboembolic Adverse Effects Associated with Cyclooxygenase-2 Selective Inhibitors and Nonselective Antiinflammatory Drugs. Anesth. Analg. 105: 1793-1804 [Abstract] [Full Text]  
• Kellogg, A. P., Wiggin, T. D., Larkin, D. D., Hayes, J. M., Stevens, M. J., Pop-Busui, R. (2007). Protective Effects of Cyclooxygenase-2 Gene Inactivation Against Peripheral Nerve Dysfunction and Intraepidermal Nerve Fiber Loss in Experimental Diabetes. Diabetes 56: 2997-3005 [Abstract] [Full Text]  
• Hoes, J N, Jacobs, J W G, Boers, M, Boumpas, D, Buttgereit, F, Caeyers, N, Choy, E H, Cutolo, M, Da Silva, J A P, Esselens, G, Guillevin, L, Hafstrom, I, Kirwan, J R, Rovensky, J, Russell, A, Saag, K G, Svensson, B, Westhovens, R, Zeidler, H, Bijlsma, J W J (2007). EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 66: 1560-1567 [Abstract] [Full Text]  
• Logan, R. (2007). Commentary: Preventing colorectal cancer with aspirin what next?. Int J Epidemiol 0: dym204v1-dym204 [Full Text]  
• Lane, N. E. (2007). Osteoarthritis of the Hip. NEJM 357: 1413-1421 [Full Text]  
• Scott, P A, Kingsley, G H, Smith, C M, Choy, E H, Scott, D L (2007). Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis 66: 1296-1304 [Abstract] [Full Text]  
• Glasser, S. P., Salas, M., Delzell, E. (2007). Importance and Challenges of Studying Marketed Drugs: What Is a Phase IV Study? Common Clinical Research Designs, Registries, and Self-Reporting Systems. J Clin Pharmacol 47: 1074-1086 [Abstract] [Full Text]  
• Gray, J., Mao, J. T., Szabo, E., Kelley, M., Kurie, J., Bepler, G. (2007). Lung Cancer Chemoprevention: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition). Chest 132: 56S-68S [Abstract] [Full Text]  
• Prevost, R. (2007). Pharmacy Review: Osteoarthritis: The Pharmacist's Perspective. AMERICAN JOURNAL OF LIFESTYLE MEDICINE 1: 271-273 [Abstract]  
• O'Byrne, K. J., Danson, S., Dunlop, D., Botwood, N., Taguchi, F., Carbone, D., Ranson, M. (2007). Combination Therapy With Gefitinib and Rofecoxib in Patients With Platinum-Pretreated Relapsed Non Small-Cell Lung Cancer. JCO 25: 3266-3273 [Abstract] [Full Text]  
• Timmers, L., Pasterkamp, G., de Kleijn, D. P.V. (2007). Microsomal Prostaglandin E2 Synthase: A Safer Target than Cyclooxygenases?. Mol. Interv. 7: 195-199 [Abstract] [Full Text]  
• Borer, J. S., Pouleur, H., Abadie, E., Follath, F., Wittes, J., Pfeffer, M. A., Pitt, B., Zannad, F. (2007). Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. Eur Heart J 28: 1904-1909 [Abstract] [Full Text]  
• Kerr, D. J., Dunn, J. A., Langman, M. J., Smith, J. L., Midgley, R. S.J., Stanley, A., Stokes, J. C., Julier, P., Iveson, C., Duvvuri, R., McConkey, C. C., the VICTOR Trial Group, (2007). Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer. NEJM 357: 360-369 [Abstract] [Full Text]  
• Klein, T., Eltze, M., Grebe, T., Hatzelmann, A., Komhoff, M. (2007). Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition. Cardiovasc Res 75: 390-397 [Abstract] [Full Text]  
• Hunt, R. H., Choquette, D., Craig, B. N., De Angelis, C., Habal, F., Fulthorpe, G., Stewart, J. I., Turpie, A. G.G., Davis, P. (2007). Approach to managing musculoskeletal pain: Acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?. cfp 53: 1177-1184 [Abstract] [Full Text]  
• Waksman, J. C, Brody, A., Phillips, S. D (2007). Nonselective Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk: Are They Safe?. The Annals of Pharmacotherapy 41: 1163-1173 [Abstract] [Full Text]  
• Reginster, J Y, Malmstrom, K, Mehta, A, Bergman, G, Ko, A T, Curtis, S P, Reicin, A S (2007). Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis 66: 945-951 [Abstract] [Full Text]  
• Armstrong, D. J., Quinn, A. D., McCausland, E. M., Wright, G. D., Finch, M. B. (2007). Does cardiovascular risk factor profile influence prescribing of non-steroidal anti-inflammatory drugs in a rheumatoid population?. Rheumatology (Oxford) 46: 1209-1210 [Full Text]  
• Salinas, G., Rangasetty, U. C., Uretsky, B. F., Birnbaum, Y. (2007). The Cycloxygenase 2 (COX-2) Story: It's Time to Explain, Not Inflame. J CARDIOVASC PHARMACOL THER 12: 98-111 [Abstract]  
• O'Dwyer, P. J., Eckhardt, S. G., Haller, D. G., Tepper, J., Ahnen, D., Hamilton, S., Benson, A. B. III, Rothenberg, M., Petrelli, N., Lenz, H.-J., Diasio, R., DuBois, R., Sargent, D., Sloan, J., Johnson, C. D., Comis, R. L., O'Connell, M. J. (2007). Priorities in Colorectal Cancer Research: Recommendations From the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. JCO 25: 2313-2321 [Abstract] [Full Text]  
• Farkouh, M E, Greenberg, J D, Jeger, R V, Ramanathan, K, Verheugt, F W A, Chesebro, J H, Kirshner, H, Hochman, J S, Lay, C L, Ruland, S, Mellein, B, Matchaba, P T, Fuster, V, Abramson, S B (2007). Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis 66: 764-770 [Abstract] [Full Text]  
• White, P. F., Sacan, O., Tufanogullari, B., Eng, M., Nuangchamnong, N., Ogunnaike, B. (2007). Effect of short-term postoperative celecoxib administration on patient outcome after outpatient laparoscopic surgery: [Effet de l'administration postoperatoire a court terme de celecoxib sur l'evolution des patients apres une chirurgie par laparoscopie sans hospitalisation]. Canadian J. Anesthesia 54: 342-348 [Abstract] [Full Text]  
• Juhn, P., Phillips, A., Buto, K. (2007). Balancing Modern Medical Benefits And Risks. Health Aff (Millwood) 26: 647-652 [Abstract] [Full Text]  
• Stark, L. A., Reid, K., Sansom, O. J., Din, F. V., Guichard, S., Mayer, I., Jodrell, D. I., Clarke, A. R., Dunlop, M. G. (2007). Aspirin activates the NF-{kappa}B signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. Carcinogenesis 28: 968-976 [Abstract] [Full Text]  
• Davidson, M. B. (2007). Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes: Response to Jellinger, Lebovitz, and Davidson . Diabetes Care 30: e18-e20 [Full Text]  
• Pyrko, P., Kardosh, A., Liu, Y.-T., Soriano, N., Xiong, W., Chow, R. H., Uddin, J., Petasis, N. A., Mircheff, A. K., Farley, R. A., Louie, S. G., Chen, T. C., Schonthal, A. H. (2007). Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Molecular Cancer Therapeutics 6: 1262-1275 [Abstract] [Full Text]  
• Fournier, L. S., Novikov, V., Lucidi, V., Fu, Y., Miller, T., Floyd, E., Shames, D. M., Brasch, R. C. (2007). MR Monitoring of Cyclooxygenase-2 Inhibition of Angiogenesis in a Human Breast Cancer Model in Rats. Radiology 243: 105-111 [Abstract] [Full Text]  
• Hopkins, T. A., Ouchi, N., Shibata, R., Walsh, K. (2007). Adiponectin actions in the cardiovascular system. Cardiovasc Res 74: 11-18 [Abstract] [Full Text]  
• Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., Taubert, K. A. (2007). Use of Nonsteroidal Antiinflammatory Drugs: An Update for Clinicians: A Scientific Statement From the American Heart Association. Circulation 115: 1634-1642 [Full Text]  
• Ong, C.K.S., Lirk, P., Tan, C.H., Seymour, R.A. (2007). An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs. Clin Med Res 5: 19-34 [Abstract] [Full Text]  
• Himmelfarb, J. (2007). Continuous Renal Replacement Therapy in the Treatment of Acute Renal Failure: Critical Assessment Is Required. CJASN 2: 385-389 [Abstract] [Full Text]  
• Bingham, C. O. III, Sebba, A. I., Rubin, B. R., Ruoff, G. E., Kremer, J., Bird, S., Smugar, S. S., Fitzgerald, B. J., O'Brien, K., Tershakovec, A. M. (2007). Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford) 46: 496-507 [Abstract] [Full Text]  
• Rahme, E., Nedjar, H. (2007). Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology (Oxford) 46: 435-438 [Abstract] [Full Text]  
• White, W. B. (2007). Cardiovascular Effects of the Cyclooxygenase Inhibitors. Hypertension 49: 408-418 [Full Text]  
• Kapoor, M., Kojima, F., Qian, M., Yang, L., Crofford, L. J. (2007). Microsomal Prostaglandin E Synthase-1 Deficiency Is Associated with Elevated Peroxisome Proliferator-activated Receptor {gamma}: REGULATION BY PROSTAGLANDIN E2 VIA THE PHOSPHATIDYLINOSITOL 3-KINASE AND AKT PATHWAY. J. Biol. Chem. 282: 5356-5366 [Abstract] [Full Text]  
• Veronesi, U., Maisonneuve, P., Decensi, A. (2007). Tamoxifen: An Enduring Star. JNCI J Natl Cancer Inst 99: 258-260 [Full Text]  
• Rawson, N. S. B. (2007). Overdose: How Excessive Government Regulation Stifles Pharmaceutical Innovation. JAMA 297: 646-647 [Full Text]  
• Saudan, M., Saudan, P., Perneger, T., Riand, N., Keller, A., Hoffmeyer, P. (2007). Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement: A PROSPECTIVE RANDOMISED TRIAL. J Bone Joint Surg Br 89-B: 155-159 [Abstract] [Full Text]  
• Brophy, J M, Levesque, L E, Zhang, B (2007). The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart 93: 189-194 [Abstract] [Full Text]  
• Binymin, K. A., Phillips, K. (2007). "To do no harm". Rheumatology (Oxford) 46: 368-370 [Full Text]  
• Zarraga, I. G. E., Schwarz, E. R. (2007). Coxibs and Heart Disease: What We Have Learned and What Else We Need to Know. J Am Coll Cardiol 49: 1-14 [Abstract] [Full Text]  
• Vidal, C., Gomez-Hernandez, A., Sanchez-Galan, E., Gonzalez, A., Ortega, L., Gomez-Gerique, J. A., Tunon, J., Egido, J. (2007). Licofelone, a Balanced Inhibitor of Cyclooxygenase and 5-Lipoxygenase, Reduces Inflammation in a Rabbit Model of Atherosclerosis. J. Pharmacol. Exp. Ther. 320: 108-116 [Abstract] [Full Text]  
• Combe, B, Landewe, R, Lukas, C, Bolosiu, H D, Breedveld, F, Dougados, M, Emery, P, Ferraccioli, G, Hazes, J M W, Klareskog, L, Machold, K, Martin-Mola, E, Nielsen, H, Silman, A, Smolen, J, Yazici, H (2007). EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66: 34-45 [Abstract] [Full Text]  
• Luyten, F P, Geusens, P, Malaise, M, De Clerck, L, Westhovens, R, Raeman, F, Vander Mijnsbrugge, D, Mathy, L, Hauzeur, J P, De Keyser, F, Van den Bosch, F (2007). A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip. Ann Rheum Dis 66: 99-106 [Abstract] [Full Text]  
• Gaffo, A., Saag, K. G., Curtis, J. R. (2006). Treatment of rheumatoid arthritis. Am J Health Syst Pharm 63: 2451-2465 [Abstract] [Full Text]  
• Anning, P. B., Coles, B., Morton, J., Wang, H., Uddin, J., Morrow, J. D., Dey, S. K., Marnett, L. J., O'Donnell, V. B. (2006). Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors. Blood 108: 4059-4062 [Abstract] [Full Text]  
• Mitchell, J. A., Lucas, R., Vojnovic, I., Hasan, K., Pepper, J. R., Warner, T. D. (2006). Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J. 20: 2468-2475 [Abstract] [Full Text]  
• Pulichino, A.-M., Rowland, S., Wu, T., Clark, P., Xu, D., Mathieu, M.-C., Riendeau, D., Audoly, L. P. (2006). Prostacyclin Antagonism Reduces Pain and Inflammation in Rodent Models of Hyperalgesia and Chronic Arthritis. J. Pharmacol. Exp. Ther. 319: 1043-1050 [Abstract] [Full Text]  
• Lanas, A, Garcia-Rodriguez, L A, Arroyo, M T, Gomollon, F, Feu, F, Gonzalez-Perez, A, Zapata, E, Bastida, G, Rodrigo, L, Santolaria, S, Guell, M, de Argila, C M, Quintero, E, Borda, F, Pique, J M, on behalf of the Investigators of the Asociacion E, (2006). Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 55: 1731-1738 [Abstract] [Full Text]  
• Madhok, R., Wu, O., McKellar, G., Singh, G. (2006). Non-steroidal anti-inflammatory drugs--changes in prescribing may be warranted. Rheumatology (Oxford) 45: 1458-1460 [Full Text]  
• Bruce, I N (2006). The influence of other drugs on coronary heart disease (CHD) risk in systemic lupus erythematosus. Lupus 15: 23-26 [Abstract]  
• Kapoor, M., Kojima, F., Qian, M., Yang, L., Crofford, L. J. (2006). Shunting of prostanoid biosynthesis in microsomal prostaglandin E synthase-1 null embryo fibroblasts: regulatory effects on inducible nitric oxide synthase expression and nitrite synthesis. FASEB J. 20: 2387-2389 [Abstract] [Full Text]  
• Buvanendran, A, Reuben, S S (2006). COX-2 inhibitors in sports medicine: utility and controversy. Br. J. Sports. Med. 40: 895-896 [Full Text]  
• Graham, D. J. (2006). COX-2 Inhibitors, Other NSAIDs, and Cardiovascular Risk: The Seduction of Common Sense. JAMA 296: 1653-1656 [Full Text]  
• McGettigan, P., Henry, D. (2006). Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2. JAMA 296: 1633-1644 [Abstract] [Full Text]  
• Zhang, J., Ding, E. L., Song, Y. (2006). Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials. JAMA 296: 1619-1632 [Abstract] [Full Text]  
• Chaiamnuay, S., Allison, J. J., Curtis, J. R. (2006). Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.. Am J Health Syst Pharm 63: 1837-1851 [Abstract] [Full Text]  
• Stafford-Smith, M. (2006). Hurry up and slow down: Lessons in drug development from the COX-2 inhibitors/Se hater et ralentir: les lecons a tirer de la production des inhibiteurs de la COX-2.. Canadian J. Anesthesia 53: 973-977 [Full Text]  
• Cheng, J. W. (2006). Use of Non-Aspirin Nonsteroidal Antiinflammatory Drugs and the Risk of Cardiovascular Events. The Annals of Pharmacotherapy 40: 1785-1796 [Abstract] [Full Text]  
• Zhang, W, Doherty, M, Bardin, T, Pascual, E, Barskova, V, Conaghan, P, Gerster, J, Jacobs, J, Leeb, B, Liote, F, McCarthy, G, Netter, P, Nuki, G, Perez-Ruiz, F, Pignone, A, Pimentao, J, Punzi, L, Roddy, E, Uhlig, T, Zimmermann-Gorska, I (2006). EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65: 1312-1324 [Abstract] [Full Text]  
• Voskuyl, A. E. (2006). The heart and cardiovascular manifestations in rheumatoid arthritis. Rheumatology (Oxford) 45: iv4-iv7 [Abstract] [Full Text]  
• Wang, M., Zukas, A. M., Hui, Y., Ricciotti, E., Pure, E., FitzGerald, G. A. (2006). Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc. Natl. Acad. Sci. USA 103: 14507-14512 [Abstract] [Full Text]  
• Solomon, S. D., Pfeffer, M. A., McMurray, J. J.V., Fowler, R., Finn, P., Levin, B., Eagle, C., Hawk, E., Lechuga, M., Zauber, A. G., Bertagnolli, M. M., Arber, N., Wittes, J., for the APC and PreSAP Trial Investigators, (2006). Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas. Circulation 114: 1028-1035 [Abstract] [Full Text]  
• Howe, C. R., Gardner, G. C., Kadel, N. J. (2006). Perioperative medication management for the patient with rheumatoid arthritis.. J Am Acad Orthop Surg 14: 544-551 [Abstract] [Full Text]  
• Gressett, S. M, Stanford, B. L, Hardwicke, F. (2006). Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract 12: 131-141 [Abstract]  
• de Leval, X., Dassesse, T., Dogne, J.-M., Waltregny, D., Bellahcene, A., Benoit, V., Pirotte, B., Castronovo, V. (2006). Evaluation of Original Dual Thromboxane A2 Modulators as Antiangiogenic Agents. J. Pharmacol. Exp. Ther. 318: 1057-1067 [Abstract] [Full Text]  
• Howard, P. A, Cheng, J. W., Crouch, M. A, Colucci, V. J, Kalus, J. S, Spinler, S. A, Munger, M. (2006). Drug Therapy Recommendations from the 2005 ACC/AHA Guidelines for Treatment of Chronic Heart Failure. The Annals of Pharmacotherapy 40: 1607-1616 [Abstract] [Full Text]  
• Arber, N., Eagle, C. J., Spicak, J., Racz, I., Dite, P., Hajer, J., Zavoral, M., Lechuga, M. J., Gerletti, P., Tang, J., Rosenstein, R. B., Macdonald, K., Bhadra, P., Fowler, R., Wittes, J., Zauber, A. G., Solomon, S. D., Levin, B., the PreSAP Trial Investigators, (2006). Celecoxib for the prevention of colorectal adenomatous polyps.. NEJM 355: 885-895 [Abstract] [Full Text]  
• Psaty, B. M., Potter, J. D. (2006). Risks and benefits of celecoxib to prevent recurrent adenomas.. NEJM 355: 950-952 [Full Text]  
• Borgdorff, P., Tangelder, G. J., Paulus, W. J. (2006). Cyclooxygenase-2 Inhibitors Enhance Shear Stress-Induced Platelet Aggregation. J Am Coll Cardiol 48: 817-823 [Abstract] [Full Text]  
• Myung, S.-J., Rerko, R. M., Yan, M., Platzer, P., Guda, K., Dotson, A., Lawrence, E., Dannenberg, A. J., Lovgren, A. K., Luo, G., Pretlow, T. P., Newman, R. A., Willis, J., Dawson, D., Markowitz, S. D. (2006). 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc. Natl. Acad. Sci. USA 103: 12098-12102 [Abstract] [Full Text]